期刊文献+

EOF与XELOX方案治疗晚期胃癌的疗效与不良反应比较 被引量:4

Comparison of EOF and XELOX treatment for advanced gastric cancer
暂未订购
导出
摘要 目的:观察奥沙利铂联合表阿霉素、氟尿嘧啶及亚叶酸钙与奥沙利铂联合卡培他滨治疗晚期胃癌的近期疗效和不良反应。方法:晚期胃癌患者75例,采用EOF方案(EOF组)化疗39例,XELOX方案(XELOX组)化疗36例,每3周为1个疗程,均于化疗2个疗程后评价疗效,对比其疗效和不良反应。结果:EOF组总有效率为43.6%,XELOX组总有效率为41.7%,2组间差异无统计学意义(P>0.05)。XELOX组手足综合征发生率明显高于EOF组(P<0.01),但都为Ⅰ、Ⅱ度。EOF组恶心呕吐、骨髓抑制、脱发的发生率均高于XELOX组(P<0.01)。结论:EOF方案和XELOX方案治疗晚期胃癌均有较好的疗效,不良反应均可耐受。XELOX方案用药方便,适合年老体弱的患者,而EOF方案在复治患者中有一定的优势。 Objective:To compare the effects and side effects of EOF(oxaliplatin combined with epirubicin and 5-Fluorouacil/leucovorin) with XELOX(oxaliplatin combined with xeloda) in treatment of patients with advanced gastric cancer.Methods:Among 75 patients with advanced gastric cancer,39 cases received EOF treatment and 36 cases received XELOX treatment.The efficacy and toxicity were evaluated after 2 therapy courses.Every therapy course included 3 weeks.Results:The overall effectve rate was 43.6% in EOF group,and 41.7% in XELOX group.There was no significant difference between the two groups(P0.05).The incidence of hand-foot syndrome in XELOX group was higher than that in EOF group(P0.01),but that of myelosuppression,nausea,vomiting and alopecie in EOX group higher than that in XEL0X group(P0.01).Conclusions:The treatment of EOF and XELOX shows well-confirmed effects for advanced gastric cancer.XELOX is more convenient and suitable for the elder or weaker patients,but EOF is more suitable for the recurrent patients.
出处 《蚌埠医学院学报》 CAS 2011年第12期1325-1327,共3页 Journal of Bengbu Medical College
关键词 胃肿瘤 奥沙利铂 表阿霉素 亚叶酸钙 卡培他滨 advanced gastric cancer oxaliplatin epirubicin leucovorin capecitabine
  • 相关文献

参考文献4

二级参考文献11

  • 1管忠震,何友兼,刘茂珍,周中梅.大剂量醛氢叶酸合并氟脲嘧啶(HDCF/5Fu)治疗晚期胃肠道癌的探讨[J].癌症,1989,8(6):421-424. 被引量:82
  • 2Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al. Phase Ⅱ trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol,2004,22:658-663.
  • 3Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin : Mechanism of action and antineoplastic activity. Sernin Oncol, 1998,25:4-12.
  • 4Raymond E, Lawrence ll, lzbicka E, et al. Activity of oxaliplatin against human tumor colony-forming units. Clin Cancer Res, 1998,4:1021- 1029.
  • 5Miwa M,Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue.Eur J Cancer, 1998,34 : 1274-1281.
  • 6Louvet C, Andre T,Tigaud JM, et al. Phase 2 study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients. J Clin Oncol,2002 ,20 :4543-4548.
  • 7Kim DY, Kim JH, Lee SH, et al. Phase 2 study of oxaliplatin ,5-fluorounacil and leucovorin in previously platinum-treated patients with advanced gastric cancer. Ann Oncol,2003,14:383-387.
  • 8Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage Ⅲ colon cancer. N Engl J Med,2005 ,352 :2696-2704.
  • 9Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:results of a large phase Ⅲ study. J Clin Oncol,2001, 19:4097-4106.
  • 10Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase Ⅲ study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol,2008 ,26 :2006-2012.

共引文献155

同被引文献31

  • 1孙燕,周际昌.临床肿瘤内科手册[M].4版.北京:人民卫生出版社,2003:568-569.
  • 2Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial [ J 1. Lancet Oncol,2011,12(7) :642 -653.
  • 3Okines AF, Ashley SE, Cunningham D, et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase I1 / 111 REAL-3 trial [ J 1. J Clin Onco1,2010,28 ( 25 ) :3945 - 3950.
  • 4The Gastric Group. Benefit of adjuvant chemotherapy for the gastric cancer[ J ]. JAMA, 2010,303 ( 17 ) : 1729-1737.
  • 5Cunningham D, Starling N, Rao S, et al. Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer[ J]. N Engl J Med ,2008,358( 1 ) :36 -46.
  • 6Kang YK,Kang WK,Shin DB,et al. Randomized phase I trial of capeeitabine/cisplatin (XP) vs continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer: efficacy and safety results [ J] . J Clin Oncol, 2006, 24(18S) : LBA4018.
  • 7Sakuramoto S, Sasako M, Yamaguehi T,et al. Adjuvant chemotherapy for gastric cancer with S-l, an oral fluoropyrimidine [ J ]. N Engl J Med,2007,357 ( 18 ) : 1810 - 1820.
  • 8Koizumi W,Narahara H,Hara T,et al. S-1 plus cisplatin versus S- 1 alone for first-line treatment of advanced gastric cancer( SPIRITS trial) : a phase I trial [ J ]. Lancet Oncol, 2008,9 ( 3 ) : 215 - 221.
  • 9Lee JL, Kang YK, Kang HJ,et al. A randomised multicentre phase lI trial of capecitabine vs S-I as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer [ J ]. Br J Cancer, 2008,99 (4) :584 - 590.
  • 10Seol YM, Song MK, Choi YJ, et al. Oral fluoropyrimidines (capecitabine or S-I ) and cisplatin as first-line treatment in elderly patients with advanced gastric cancer:a retrospective study [ J]. Jpn J Clin Oncol,2009,9( 1 ) :43 -48.

引证文献4

二级引证文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部